Nvidias Revenue Growth and Viking Therapeutics Stock Surge Explained

Leading AI chip maker Nvidia has achieved triple-digit increases in earnings and sales this year. But Viking Therapeutics, a different biotech stock, has been rising as well; it has increased 247% since the year`s beginning. Viking Therapeutics is developing injectable and oral GIP and GLP-1 receptor agonists for metabolic and endocrine disorders, targeting weight loss. The company has recently advanced VK-2735, its injectable candidate, into a phase 3 trial and has scheduled an end-of-phase 2 meeting with the U.S. Food and Drug Administration. The drug has shown promising results in the phase 2 trial, resulting in up to 15% weight loss after 13 weeks of treatment. The weight loss drug market is expected to grow by 16 to reach $100 billion by the end of the